Intracranial delivery of MANF is neuroprotective but not feasible in ischemic stroke patients due to increased risk of hemorrhage caused by thrombolytic treatment and the infarct itself, and therefore it is vital to explore the possibility for non-invasive delivery. The gene discussed is MANF; the disease is ischemic stroke.